American Well Corp

United States

AMWL▲

DarioHealth Wins New Jersey Health Plan Contract Covering 1.5M Lives

DarioHealth secured a contract with one of New Jersey's largest health plans, representing approximately 1.5 million covered lives, through its channel partnership with Amwell. The program, which covers Dario's cardiometabolic suite and provider-backed care, is expected to launch and begin generating revenue in the first quarter of 2027. The deal marks DarioHealth's third large state health plan contract through Amwell in the past 12 months, following agreements in Arizona and Florida. The stock traded about 4% higher in Thursday pre-market hours.

DRIO ▲AMWL ▲

DRIO · Demand · Positive DarioHealth won a New Jersey health plan contract covering ~1.5M lives for its cardiometabolic suite, its third large state plan deal via Amwell in 12 months.

AMWL · Demand · Positive DarioHealth's new state health plan contract was secured through its channel partnership with Amwell, driving end-customer adoption of Amwell's platform.

Read original ↗

Seeking Alpha·17dRead more →

United States

AMWL▲

Amwell Receives VA Letter of Intent for Digital Health Platform

Amwell announced that the Department of Veterans Affairs has declared its intent for the company to deploy its virtual health platform within the VA enterprise, aiming to modernize the VA's digital health infrastructure and improve care for over nine million Veteran beneficiaries. The Letter of Intent follows a comprehensive evaluation in which the VA determined that Amwell's platform aligns with its strategic objectives, citing capabilities in scalable video consultations, interoperability, cybersecurity compliance, and integrated care delivery. Amwell's Chairman and CEO, Dr. Ido Schoenberg, expressed gratitude and honor at the VA's choice. However, the Letter of Intent is non-binding, and any formal agreement will depend on negotiating a definitive contract and meeting federal procurement requirements.

AMWL ▲

AMWL · Demand · Positive VA Letter of Intent for deploying its virtual health platform, a concrete demand signal.

Read original ↗

GlobeNewswire·26dRead more →

United States

AMWL▲

Biotech Stocks Surge on Earnings and Debuts

Several biotech companies posted sharp gains on Wednesday, led by Attovia Therapeutics' 28% surge on its Nasdaq debut and American Well's 25% jump after narrowing its quarterly loss. Attovia priced its IPO at $17 per share and closed at $21.90, while American Well reported a net loss of $9.6 million, or $0.59 per share, down from $19.5 million, or $1.24 per share, a year earlier, though revenue fell to $52.0 million from $70.9 million. Perrigo swung to a net income of $74.5 million, or $0.53 per share, from a loss of $8.4 million, or $0.06 per share, despite a slight revenue dip to $1.02 billion. UroGen Pharma climbed over 16% after total revenue more than doubled to $72.5 million, driven by its bladder cancer drug ZUSDURI, and its net loss narrowed to $14.4 million from $49.9 million. Geron rose 21% as net product revenue increased to $57.5 million from $49.0 million, fueled by higher RYTELO sales, and it forecast full-year RYTELO revenue of $220 million to $240 million.

AMWL ▲GERN ▲PRGO ▲URGN ▲

Attovia Therapeutics, Inc. · Capital · Positive IPO priced at $17 and closed at $21.90, surging 28% on debut

AMWL · Capital · Positive Narrowed quarterly loss and reduced net loss per share

GERN · Demand · Positive Higher RYTELO sales and raised full-year revenue forecast

PRGO · Capital · Positive Swung to net income despite slight revenue dip

URGN · Demand · Positive Total revenue more than doubled driven by bladder cancer drug ZUSDURI

Read original ↗

RTTNews·59dRead more →

Biotech & Genomic Medicine

Biotech Stocks AMWL, CUE, ICCC, SRRK, FTH Hit 52-Week Highs

Several biotech stocks reached 52-week highs on July 10, 2026, driven by regulatory updates and quarterly results. American Well Corporation hit $10.16, closing at $9.91, after a Nature report validated its SilverCloud platform and it facilitated a DarioHealth insurer agreement, though full-year 2026 revenue is expected at $195 million to $205 million, below 2025's $249.3 million. Cue Biopharma reached $45.50 and announced a roughly $50 million private placement, while advancing CUE-221 in a Phase 2 allergy study and planning an IND for CUE-401. ImmuCell climbed to $11.59 after reporting unaudited second-quarter sales of $7.2 million, an 11.5% year-over-year increase, with $4.9 million from Tri-Shield First Defense. Scholar Rock hit $58.49, up 3.33%, as its BLA for Apitegromab in SMA is under FDA review with a decision expected by September 30, 2026. Faeth Therapeutics touched $36.89, advancing the PIKTOR combination therapy in a Phase 1/2 breast cancer trial with interim data due in 2027 and a Phase 2 endometrial cancer trial with topline data expected in the second half of 2026.

CUE ▲ICCC ▲SRRK ▲AMWL FTH ▲

Biotech & Genomic Medicine ▲

About megatrends

Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Regulation

Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Capital

Biotech & Genomic Medicine › Oncology Therapeutics Capital

Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Capital

CUE · Capital · Positive Announced roughly $50 million private placement and advanced CUE-221 in Phase 2 allergy study.

ICCC · Demand · Positive Reported unaudited Q2 sales of $7.2 million, an 11.5% YoY increase, with $4.9 million from Tri-Shield First Defense.

SRRK · Regulation · Positive BLA for Apitegromab in SMA under FDA review with decision expected by September 30, 2026.

AMWL · Demand · Neutral Nature report validated SilverCloud platform and facilitated DarioHealth insurer agreement, but full-year 2026 revenue expected below 2025.

FTH · Technology · Positive Advancing PIKTOR combination therapy in Phase 1/2 breast cancer trial with interim data due in 2027 and Phase 2 endometrial cancer trial with topline data expected H2 2026.

Read original ↗

RTTNews·83dRead more →